HFCAN
Latest Information Update: 11 Jul 2023
At a glance
- Originator HighField Biopharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 11 Jul 2023 Discontinued - Preclinical for Unspecified in China (Parenteral) (HighField Biopharmaceuticals pipeline, July 2023)
- 31 May 2022 Preclinical trials in Unspecified in China (unspecified route) (HighField Biopharmaceuticals pipeline; May 2022)